(Reuters) - Drugmaker Indivior Plc on Thursday raised its profit and revenue guidance for the full year as its blockbuster opioid drug Suboxone lost market share at a lower pace than expected, bolstering its first-half performance.
The company, spun off from Reckitt Benckiser in 2014, expects net income for 2019 in the range of $80 million to $130 million, up from a prior expectation of between a loss of $40 million and $10 million.
It also said its generic version of branded Suboxone was performing well.
Separately, Reckitt said it would pay up to $1.4 billion to resolve all U.S. federal investigations related to Indivior.
Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur
Our Standards: The Thomson Reuters Trust Principles.